EFFECT OF ERYTHROPOIETIN ON CYTOKINE PRODUCTION BY STEM CELLS

Erythropoietin (EPO) is mainly used to stimulate erythropoiesis. Its cytoprotective effects upon other cells of the human body and animals were recently shown, in particular, anti-apoptotic effect was observed. EPO effect upon the cells is mediated by interaction with erythropoietin receptor, with a complex forming a heterodimeric bond with β-common chain (CD131). In the present work, we studied the changes in erythropoietin receptor expression, and production spectrum of biologically active molecules in bone marrow mononuclear cells (BM-MNC) of patients with coronary heart disease. The flow cytometric assays showed that short-term incubation of BM-MNC with erythropoietin caused increased expression of the erythropoietin receptors on hematopoietic stem cells and tended to reduce the number of endothelial progenitor cells carrying the erythropoietin receptors. Solid-phase enzyme immunoassay in conditioned media from BM-MNC revealed that long-term (72 hours) exposure of BM-MNC to erythropoietin promoted increased production of IL-1β, PDGF-AB, and Epo, if compared to the basal production level (p < 0.05). Short-term incubation of BM-MNC with erythropoietin (60 minutes) caused a significant increase in the IL-1β, PDGF-AB and CXCL-12 / SDF-1α production levels, as well as significant reduction in the IL-10 production levels compared to the basal levels (p < 0.05).

1. Anagnostou A., Lee E.S., Kessimian N., Levinson R., Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc. Natl. Acad. Sci. USA, 1990, Vol. 87, no. 15, pp. 5978-5982.

2. Bennis Y., Sarlon-Bartoli G., Guillet B., Hubert L., Pellegrini P., Velly L., Blot-Chabaud M., Dignat-Georges F., Sabatier F., Pisano P. Priming of late endothelial progenitor cells with erythropoietin before transplantation requires the CD131 receptor subunit and enhances their angiogenic potential. J. Thromb. Haemost., 2012, Vol. 10, pp. 19141928.

3. Ercan E., Bagla A.G., Aksoy A., Gacar G., Unal Z.S., Asgun H.F., Karaoz E. In vitro protection of adipose tissue-derived mesenchymal stem cells by erythropoietin. Acta Histochem., 2014, Vol. 116, no. 1, pp. 117-125.

4. Fisher S.A., Doree C., Brunskill S.J., Mathur A., Martin-Rendon E. Bone marrow stem cell treatment for ischemic heart disease in patients with no option of revascularization: a systematic review and meta-analysis. PLoS ONE, 2013, Vol. 8, no. 6, e64669. doi: 10.1371/journal.pone.0064669.

5. George J., Goldstein E., Abashidze A., Wexler D., Hamed S., Shmilovich H., Deutsch V., Miller H., Keren G., Roth A. Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinasedependent manner. Cardiovasc. Res., 2005, Vol. 68, pp. 299-306.

6. Heeschen C., Aicher A., Lehmann R., Fichtlscherer S., Vasa M., Urbich C., Mildner-Rihm C., Martin H., Zeiher A.M., Dimmeler S. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood, 2003, Vol. 102, no. 4, pp. 1340-1346.

7. Henry T.D., Schaer G.L., Traverse J.H., Povsic T.J., Davidson C., Lee J.S., Costa M.A., Bass T., Mendelsohn F., Fortuin F.D., Pepine C.J., Patel A.N., Riedel N., Junge C., Hunt A., Kereiakes D.J., White C., Harrington R.A., Schatz R.A., Losordo D.W., and the ACT34-CMI Investigators. Autologous CD34 + cell therapy for refractory angina: 2-year outcomes from the ACT34-CMI study. Cell Transplant., 2016, Vol. 25, pp. 1701-1711.

8. Hirata A., Minamino T., Asanuma H., Fujita M., Wakeno M., Myoishi M., Tsukamoto O., Okada K., Koyama H., Komamura K., Takashima S., Shinozaki Y., Mori H., Shiraga M., Kitakaze M., Hori M. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J. Am. Coll. Cardio, 2006, Vol. 48, pp. 176-184.

9. Hu R., Cheng Y., Jing H., Wu H. Erythropoietin promotes the protective properties of transplanted endothelial progenitor cells against acute lung injury via PI3K/Akt pathway. Shock, 2014, Vol. 42, no. 4, pp. 327-336.

10. Jang J., Yun J.Y., Hur1J., Kang J.A., Choi J.I., Ko S.B., Lee J, Kim J.Y., Hwang I.C., Park Y.B., Kim H.S. Erythropoietin priming improves the vasculogenic potential of G-CSF mobilized human peripheral blood mononuclear cells. Cardiovasc. Res., 2014, Vol. 104, pp. 171-182.

11. Kimakova P., Solar P., Solarova Z., Komel R., Debeljak N. Erythropoietin and its angiogenic activity. Int. J. Mol. Sci., 2017, Vol. 18, no. 7, 1519. doi: 10.3390/ijms18071519.

12. Lisowska K.A., Debska-Slizien A., Bryl E., Rutkowski B., Witkowski J.M. Erythropoietin receptor is expressed on human peripheral blood T and B lymphocytes and monocytes and is modulated by recombinant human erythropoietin treatment. Artif. Organs, 2010, Vol. 34, pp. 654-662.

13. Madigan M., Atoui R. Therapeutic use of stem cells for myocardial infarction. Bioengineering (Basel), 2018, Vol. 5, no. 2, E28. doi: 10.3390/bioengineering5020028.

14. Mozid A., Yeo C., Arnous S., Ako E., Saunders N., Locca D., Brookman P., Archbold R.A., Rothman M., Mills P., Agrawal S., Martin J., Mathur A. Safety and feasibility of intramyocardial versus intracoronary delivery of autologous cell therapy in advanced heart failure: the REGENERATE-IHD pilot study. Regen. Med., 2014, Vol. 9, no. 3, pp. 269-278.

15. Pavo I.J., Michel-Behnke I. Clinical cardiac regenerative studies in children. World J. Cardiol., 2017, Vol. 9, no. 2, pp. 147-153.

16. Rupp S., Jux C., Bonig H., Bauer J., Tonn T., Seifried E., Dimmeler S ., Zeiher A.M., Schranz D. Intracoronary bone marrow cell application for terminal heart failure in children. Cardiol. Young, 2012, Vol. 22, no. 5, pp. 558-563.

17. Seurder D., Radrizzani M., Turchetto L., Lo Cicero V., Soncin S., Muzzarelli S., Auricchio A., Moccett T. Combined delivery of bone marrow-derived mononuclear cells in chronic ischemic heart disease: rationale and study design. Clin. Cardiol., 2013, Vol. 36, no. 8, pp. 435-441.